Highlights of the 2018 Annual European Neuroendocrine Tumor Society (ENETS) Congress

BJMO - volume 12, issue 5, september 2018

W. Lybaert MD, T. Vandamme MD, G. Boons , T. Rondou , M. Twickler , I. Dero MD, F. van Fraeyenhove MD, L. De Backer , D. Van Genechten , M. Peeters MD, PhD

March 7-9, 2018, Barcelona, Spain.

(BELG J MED ONCOL 2018:12(5):252–262)

Read more

Highlights of the European Neuroendocrine Tumor Society (ENETS) Congress

BJMO - volume 11, issue 3, may 2017

W. Lybaert MD, M. Simoens , W. Demey MD, F. van Fraeyenhove MD, T. Vandamme MD, L. De Backer , M. Peeters MD, PhD

Barcelona, 8-10 March 2017.

(BELG J MED ONCOL 2017;11(3):129–133)

Read more

Bone complications in cancer patients

BJMO - volume 8, issue 1, march 2014

D. Schrijvers MD, PhD, A. Vandebroek MD, N. Blockx MD, F. van Fraeyenhove MD

Bone complications are frequently observed in cancer patients. They may be the result of the disease or due to the anticancer treatment. Osteoporosis is seen in up to 30% of cancer patients depending on tumor type and treatment and screening for osteoporosis is indicated in selected patients. It should be prevented by the use of calcium and vitamin D and exercising programs and, if present, should be adequately treated by drugs registered for the treatment of osteoporosis. Bone metastases are observed in up to 75% of metastatic cancer patients depending on the tumor type. Skeletal-related complications, occurring in 50–70% in patients with bone metastases, can be prevented and delayed by the use of bisphosphonates or denosumab. Prevention of the development of bone metastases has been shown by anti-tumor treatment while the role of modification of the micro-environment by bisphosphonates and denosumab needs further study.

(BELG J MED ONCOL 2014;8(1):3–8)


Read more